About HemaStem

Established in 2000, HemaStem is a privately held Canadian Federal Corporation.  HemaStem brought to market its first commercialized adult stem cell platform in 2002 and fully incorporated into HemaStem Therapeutics Inc. in 2004.  

HemaStem first stage placental umbilical cord blood stem cell isolation technology known as HemaStem, is based on licenced US patents # 5,004,681. # 5,192,553 , # 6,461,645 , # 6,569,427, and # 6,605, 275.

At HemaStem we have researched and developed procedures and technologies for the isolation, preservation, and therapeutic use of adult stem cells. In particular, our focus is the isolation, cultivation and storage of adult stem cells .

The name HemaStem (pronounced hee-mah-stem) is derived from the Greek word 'haima' which means blood and combined with the english word stem.  HemaStem & 'Today's Miracles Are Tomorrows Treatments' is a registered trademark of HemaStem Inc.  Our logo consist of a dark solid circle and surround by three inverted crescents depicts the isolation and harnessing of the potential possibilities of stem cells biology.  

At HemaStem we believe that it will be advantageous for families and patients to have a supply of healthy stem cells stored in a biological bank which may be used for future stem cell therapies as needed for that patient.  These banked stem cells would be compatible with the patient's own genetics to prevent problems with immunogenic incompatibilities like graft rejection. Because they will be harvested prior to the onset of disease, they will be free from disease or muated genetics and they can be used for restorative purposes. 

At HemaStem we believe that 'today's miracles are tomorrow's treatments'